CHICAGO - MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company with a market capitalization of $49.4 million, has announced updated data from its Phase 2 clinical ...
MAIA Biotechnology, Inc. (NYSEAMERICAN: MAIA) disclosed information relating to its Phase 2 THIO-101 trial in advanced non-small cell lung cancer through a press release on February 4, 2025. According ...
MAIA Biotechnology, Inc. is a clinical stage biotechnology company that is engaged in the discovery, development and commercialization of therapies targeting cancer. Its product, THIO, is an ...
MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) recently disclosed updates to the employment agreements of key executive officers in a Form 8-K filing dated February 1, 2025. The company entered into ...
Hosted on MSN6mon
Philadelphia Native Maia Weintraub is Product of a ‘Tiger Mom’ and Now An Olympic Gold Medalist in FencingMaia Weintraub is a 2022 NCAA women’s foil champion and now a member of the gold medal-winning 2024 U.S. Olympic fencing team. Her success in sports and in life can be heavily credited to her ...
MAIA's preclinical results in HCC ... our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and ...
Round Rock, Texas] - Maia Homes , a trailblazer in animal-inspired maximalist home decor, proudly presents its latest collection of handcrafted home ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback